Revision: May 5, 2022, 9:09 a.m.
Sen. Sherman, Dist 24
Sen. Whitley, Dist 15
May 3, 2022
2022-1922s
05/04
Floor Amendment to HB 1022
Amend the title of the bill by replacing it with the following:
AN ACT establishing a commission to study the use of Ivermectin to treat Covid-19.
Amend the bill by replacing all after the enacting clause with the following:
1 New Subdivision; Commission to Study the Use of Ivermectin to Treat Covid-19 Established. Amend RSA 126-A by inserting after section 97 the following new subdivision:
Commission to Study the Use of Ivermectin to Treat Covid-19
126-A:98 Commission to Study the Use of Ivermectin to Treat Covid-19. There is established a commission to study use of Ivermectin to treat Covid-19.
I. The members of the commission shall be as follows:
(a) Three members of the house of representatives, appointed by the speaker of the house of representatives, at least one of whom shall be a member of the house health, human services and elderly affairs committee and one of whom shall be a member of the executive departments and administration committee.
(b) One member of the senate, appointed by the president of the senate.
(c) The commissioner of the department of health and human services, or designee.
(d) A representative of the New Hampshire board of pharmacy, appointed by the board.
(e) A representative of the board of nursing, appointed by the board.
(f) A representative of the board of medicine, appointed by the board.
(g) A representative of the New Hampshire Medical Society, appointed by the society.
(h) A representative of the New Hampshire Hospital Association, appointed by the association.
(i) A representative of the New Hampshire Nurse Practitioners Association, appointed by the association.
(j) A representative of the New Hampshire Pharmacist Association, appointed by the association.
(k) Two members of the public, one of whom shall be appointed by the senate president and one of whom shall be appointed by the speaker of the house of representatives.
II. Legislative members of the commission shall receive mileage at the legislative rate when attending to the duties of the commission.
III. The commission shall examine national data on the use of Ivermectin to treat Covid-19, relevant studies around the use of Ivermectin and work already being conducted by other states standing orders.
IV. The members of the study commission shall elect a chairperson from among the members. The first meeting of the commission shall be called by the senate member. The first meeting of the commission shall be held within 45 days of the effective date of this section. A majority of commission members shall constitute a quorum.
V. The commission shall report its findings and any recommendations for proposed legislation to the president of the senate, the speaker of the house of representatives, the senate clerk, the house clerk, the governor, and the state library on or before November 1, 2022.
2 Repeal. RSA 126-A:98 and the subdivision heading preceding RSA 126-A:98 are repealed.
I. Section 2 of this act shall take effect December 31, 2022.
II. The remainder of this act shall take effect upon its passage.
2022-1922s
AMENDED ANALYSIS
This bill establishes a commission to study the use of Ivermectin to treat Covid-19.